Simultaneously, along with the decrease in the CLL count, the trend of increasing HLA-DR expression on classical and intermediate monocytes (Fig. 5A), as well as the non-classical monocytes and CD4+ and CD8+ T cells (data not shown), was detected during the first year of ibrutinib treatment, but not with idelalisib. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.